Dongwha Pharm.Co.,Ltd (KRX:000020)

Market Cap	183.49B +4.4%
Revenue (ttm)	493.33B +15.1%
Net Income	7.59B -1.0%
EPS	273.72 -1.2%
Shares Out	27.72M
PE Ratio	24.19
Forward PE	n/a
Dividend	180.00 (2.77%)
Ex-Dividend Date	Dec 29, 2025

Volume	277,925
Average Volume	114,548
Open	6,590.00
Previous Close	6,500.00
Day's Range	6,470.00 - 6,685.00
52-Week Range	5,560.00 - 7,140.00
Beta	0.33
RSI	73.32
Earnings Date	Feb 20, 2026

About Dongwha Pharm.Co.,Ltd

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1897
• Employees: 827
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000020

Financial Performance

In 2024, Dongwha Pharm.Co.,Ltd's revenue was 464.87 billion, an increase of 28.74% compared to the previous year's 361.11 billion. Earnings were 5.56 billion, a decrease of -79.72%.